Literature DB >> 12731421

[21-year-old patient with myocardial infarct, transient cerebral ischemia and thrombocytopenia].

A Rank1, L Lindner, E Hiller.   

Abstract

We report on a case of a young female soccer player who first experienced a transient ischemic attack at the age of 21 and then suffered an acute myocardial infarction accompanied by thrombocytopenia 6 months later. The underlying cause was antiphospholipid syndrome. This clinical picture is caused by a very heterogeneous group of antiphospholipid antibodies, which interfere with plasmatic coagulation at various sites and are able to activate thrombocytes, endothelial cells, and monocytes. This leads to a thrombophilic condition with clinical manifestation of recurrent venous thromboses, arterial embolisms, or premature birth or miscarriage. The main therapeutic options are thus anticoagulation, heparins, and aspirin. Steroids are recommended for cases of pronounced thrombocytopenias; if treatment fails, immunosuppressants are also advisable. The antiphospholipid syndrome should be kept in mind especially in cases of young patients with thromboembolic events since the presence of antiphospholipid antibodies can be detected in 10-20% of this patient group and effective therapy after diagnosis lowers the rate of recurrence.

Entities:  

Mesh:

Year:  2003        PMID: 12731421     DOI: 10.1007/s00108-002-0811-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  17 in total

1.  Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population.

Authors:  W Shi; S A Krilis; B H Chong; S Gordon; C N Chesterman
Journal:  Aust N Z J Med       Date:  1990-06

2.  The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants.

Authors:  P Thiagarajan; V Pengo; S S Shapiro
Journal:  Blood       Date:  1986-10       Impact factor: 22.113

3.  Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis.

Authors:  Hermine I Brunner; Wee-Shian Chan; Jeffrey S Ginsberg; Brian M Feldman
Journal:  J Rheumatol       Date:  2002-03       Impact factor: 4.666

4.  Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation.

Authors:  J Nimpf; H Wurm; G M Kostner
Journal:  Atherosclerosis       Date:  1987-02       Impact factor: 5.162

5.  Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia.

Authors:  P Nencini; M C Baruffi; R Abbate; G Massai; L Amaducci; D Inzitari
Journal:  Stroke       Date:  1992-02       Impact factor: 7.914

6.  Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.

Authors:  G Finazzi; V Brancaccio; M Moia; N Ciaverella; M G Mazzucconi; P C Schinco; M Ruggeri; E M Pogliani; G Gamba; E Rossi; F Baudo; C Manotti; A D'Angelo; G Palareti; V De Stefano; M Berrettini; T Barbui
Journal:  Am J Med       Date:  1996-05       Impact factor: 4.965

7.  Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study.

Authors:  A Lynch; R Marlar; J Murphy; G Davila; M Santos; J Rutledge; W Emlen
Journal:  Ann Intern Med       Date:  1994-03-15       Impact factor: 25.391

8.  Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation.

Authors:  A L Campbell; S S Pierangeli; S Wellhausen; E N Harris
Journal:  Thromb Haemost       Date:  1995-03       Impact factor: 5.249

9.  Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation.

Authors:  M E Martinuzzo; J Maclouf; L O Carreras; S Lévy-Toledano
Journal:  Thromb Haemost       Date:  1993-10-18       Impact factor: 5.249

Review 10.  [Antiphospholipid antibody syndrome].

Authors:  R Schmidt; E H Scheuermann; A Viertel; H Geiger; I Scharrer
Journal:  Med Klin (Munich)       Date:  1999-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.